Sign in
TerminatedPhase 2/3

Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation

Key facts

Who runs it
University of Zurich
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2/3
People taking part
24 people enrolled
Started
15 Jun 2022
Ended
4 Mar 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Application of Tralokinumab
Record updated
6 February 2026
Why it stopped
treatment group completed but insufficient recruitment control group

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Inclusion criteria (patients):; Moderate to severe AD; EASI < 50; 18-65 years old; Subject is capable of giving informed consent; Signed informed consent
  • No diagnosis or history of atopic dermatitis
  • 18-65 years old
  • Subject is capable of giving informed consent
  • Signed informed consent

Who cannot take part

  • Use of systemic corticosteroids or systemic immunosuppressive/immunomodulating drugs within four weeks prior to start of the study
  • Use of tanning beds or phototherapy within 6 weeks prior to start of the study
  • Known or suspected non-compliance, drug or alcohol abuse,
  • Previous enrolment into the current study,
  • History of cancer except for treated basal cell or spinal cell carcinoma of the skin
  • Active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Female patients of childbearing potential who are pregnant or breast feeding or planning a pregnancy during the duration of the trial and/or not practicing acceptable birth control for the duration of the trial
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA however remains insufficiently understood. A better understanding of the mechanisms underlying the clinical effects of tralokinumab would be of great clinical benefit since it may ultimately help us to identify more precisely candidate patients who may benefit from a therapy with tralokinumab.

The 2 groups in the trial

  • Healthy armNo study treatment, for comparison

    Healthy controls

  • TralokinumabExisting treatment, for comparison

    Patients with AD

    Treatment: Application of Tralokinumab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation (TRALIS)
Record updated
6 February 2026